Fertility preservation in >1,000 patients: patient’s characteristics, spectrum, efficacy and risks of applied preservation techniques
- 429 Downloads
Data on the characteristics of female patients counselled for fertility preservation and the efficacy and risk of the applied procedures are still poor. We therefore analysed the registry of a network of 70 infertility centers which are involved in fertility preservation in Germany, Switzerland and Austria, called FertiPROTEKT (hhtp://www.fertiprotekt.eu).
Materials and methods
1,280 counselled patients (15–40 years) were analysed regarding characteristics and different fertility preservation treatments before cytotoxic therapy in 2007–2009.
34.8% of the counselled patients were diagnosed with breast cancer, 30.5% with Hodgkin’s lymphoma, 25.4% with other malignancies and 9.3% with non-malignant diseases. 89.6% of the treated breast cancer patients were 25–40 years of age, and 87.5% of the lymphoma patients were 15–30 years of age. At the time of counselling, 85.3% of the breast cancer patients and 92.7% of the lymphoma patients were childless.
1,080 patients received a single or combined therapy such as GnRH agonists (n = 823), cryopreservation of ovarian tissue (n = 500), ovarian stimulation (n = 221) and transposition of the ovaries (n = 24). Only one severe complication, requiring postponement of the chemotherapy, was documented. In stimulated patients, 2,417 oocytes (mean n = 11.6, SD ± 7.7) were received. Fertilisation rate per received oocyte was 61.3%.
Fertility preservation programmes mainly involve women without children, diagnosed with breast cancer or Hodgkin’s lymphoma. Fertility preservation techniques can be applied with low risk. The limited and age-dependant success rate of the different therapies require individualised approaches of single or combined fertility preservation techniques.
KeywordsFertility preservation IVF Cancer Oocyte GnRH Cryopreservation
We would like to thank all members of the FertiPROTEKT network for data acquisition. A list of all members is available on the network’s website, under http://www.fertiprotekt.eu. We are greatly indebted to Mrs. Elizabeth Kraemer for reviewing our manuscript.
Conflict of interest
We declare that we have no conflict of interest.
- 8.Huober-Zeeb C, Lawrenz B, Popovici R, Strowitzki T, Germeyer A, Stute P, v Wolff M (2010) Improving fertility preservation in cancer: ovarian tissue cryobanking followed by ovarian stimulation can be efficiently combined. Fertil Steril (in press)Google Scholar
- 9.FertiPROTEKT (2009) Network for fertility preservation before chemo- and radiotherapy. Available at: http://www.fertiprotekt.de/index.php?lang=uk. Accessed 13 November 2009
- 11.Behringer K, Breuer K, Reineke T, May M, Nogova L, Klimm B, Schmitz T, Wildt L, Diehl V, Engert A, German Hodgkin’s Lymphoma Study Group (2005) Secondary amenorrhea after Hodgkin’s lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 23:7555–7564CrossRefPubMedGoogle Scholar
- 22.http://www.deutsches-ivf-register.de. Jahrbuch Deutsches IVF-Register 2008
- 24.Von Wolff M, Donnez J, Hovatta O, Keros V, Maltaris T, Montag M, Salle B, Sonmezer M, Andersen CY (2009) Cryopreservation and autotransplantation of human ovarian tissue prior to cytotoxic therapy–A technique in its infancy but already successful in fertility preservation. Eur J Cancer 45(9):1547–1553CrossRefGoogle Scholar